Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment
| Autor: | Jiezuan Yang, Nengneng Zheng, Hejun Mao, Dong Yan, Jianqin He, Xiao Hu, Renyong Guo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Chemokine Time Factors Gastroenterology Article 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Chronic hepatitis Antigen Internal medicine medicine Humans Hepatitis B e Antigens Seroconversion Multidisciplinary Receiver operating characteristic biology business.industry Interleukin Entecavir Middle Aged Chemokine CXCL10 030104 developmental biology HBeAg Immunology biology.protein Female 030211 gastroenterology & hepatology business Follow-Up Studies medicine.drug |
| Zdroj: | Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/srep37015 |
| Popis: | The aim of this study was to determine the correlation between dynamic changes in serum cytokine/chemokine expression levels in response to entecavir (ETV) treatment and HBV e antigen (HBeAg) seroconversion in patients with chronic hepatitis B (CHB). Four cytokines (interleukin [IL]-4, IL-6, IL-8, and interferon-γ) and five chemokines (macro-phage inflammatory protein [MIP]-1α, MIP-1β, platelet derived growth factor-BB, and interferon-inducible protein 10 [IP-10]) before ETV therapy and at 3, 6, 12, 24, 36 and 60 months during therapy in 105 CHB patients were analyzed. The results showed that the low decrease rate of IP-10 levels after 1 year of ETV treatment was an independent predictor of HBeAg seroconversion at year 5 (Hazard ratio = 0.972). The area under the receiver operating characteristic curves for the decrease rate of IP-10 levels after 1 year of treatment to discriminate a year-5 HBeAg seroconversion was 0.752 (p = 0.005). The results indicate that higher IP-10 level at year one of ETV treatment is associated with an increased probability of HBeAg seroconversion. Quantification of IP-10 during ETV treatment may help to predict long-term HBeAg seroconversion in patients with CHB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|